SCHEMBL3056367

SCHEMBL3056367

[CH2]Cc1ccc(S(=O)(=O)N(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.53
LMNA P02545 5/20 0.53
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NPC1 O15118 1/20 0.43
TNF P01375 1/20 0.43
RAB9A P51151 1/20 0.43
NOD1 Q9Y239 1/20 0.43
NAMPT P43490 1/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
LOX P28300 1/20 0.42
KMT2A Q03164 1/20 0.42
TSHR P16473 1/20 0.42
MAPT P10636 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482607 0.81 LMNA (0.60) ALDH1A1LMNAHTTSMN1; SMN2NPC1
SCHEMBL6710649 0.80 LMNA (0.59) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
SCHEMBL2248882 0.79 CA1 (0.55) ALDH1A1LMNAHTTSMN1; SMN2NPC1
SCHEMBL3069358 0.79 LMNA (0.53) ALDH1A1LMNAHTTSMN1; SMN2NPC1
SCHEMBL3407737 0.79 ALDH1A1 (0.53) ALDH1A1LMNAHTTSMN1; SMN2NPC1
SCHEMBL15699683 0.79 ALDH1A1 (0.53) ALDH1A1LMNAHTTSMN1; SMN2NPC1
SCHEMBL1146125 0.79 PSIP1 (0.59) ALDH1A1LMNAHTTSMN1; SMN2NPC1
SCHEMBL8337020 0.78 CA2 (0.60) ALDH1A1LMNAHTTSMN1; SMN2KMT2A
SCHEMBL11539408 0.78 LMNA (0.55) ALDH1A1LMNAHTTSMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL5728345 0.78 CA1 (0.59) ALDH1A1LMNAHTTSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-2207773-B1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMA CO LTD (JP) 2012-07-11 EP disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed
US-6399658-B1 REDUCING DRUG SIDE EFFECT SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2002-06-04 US disclosed
EP-1004304-A1 COMPOSITION CONTAINING ASCORBIC ACID SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 ALDH1A1 741/4885LMNA 1184/4885HTT 1225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.